<DOC>
	<DOCNO>NCT00520494</DOCNO>
	<brief_summary>The objective study assess efficacy safety Vivaglobin previously untreated patient ( PUPs ) primary immunodeficiency ( PID ) 25-week observation period . The purpose investigate whether PUPs respond subcutaneous immunoglobulin ( SCIG ) treatment adequate trough level without first receiving immunoglobulin intravenous route demonstrate 100 mg immunoglobulin G/kg body weight ( IgG/kg bw ) administer 5 consecutive day ( i.e . result total dose 500 mg IgG/kg bw ) result IgG increase ≥ 5 g/L Day 12 initiation SCIG therapy .</brief_summary>
	<brief_title>Efficacy Safety Vivaglobin® Previously Untreated Patients With Primary Immunodeficiency</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Key Written inform consent , ageadapted Male female age 1 70 year Diagnosis primary humoral immunodeficiency No prior immunoglobulin substitution therapy IgG level &lt; 5 g/L screen Women childbearing potential must use medically approved contraception must negative urine pregnancy test screen Key Evidence serious infection screen first treatment Bleeding disorder require medical treatment Any medical disorder cause secondary immune disorder , autoimmune neutropenia , clinically significant defect cell mediate immunity Any condition likely interfere evaluation study drug satisfactory conduct trial</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Previously Untreated Patient ( PUP )</keyword>
	<keyword>Primary Immunodeficiency ( PID )</keyword>
	<keyword>CVID</keyword>
	<keyword>XLA</keyword>
	<keyword>Subcutaneous immunoglobulin ( SCIG )</keyword>
	<keyword>IgG trough level</keyword>
	<keyword>Quality life</keyword>
	<keyword>Common variable immunodeficiency ( CVID )</keyword>
	<keyword>X-linked agammaglobulinemia ( XLA )</keyword>
</DOC>